Ceftriaxone

别名: 头孢曲松;三嗪噻肟头孢菌素;头孢三嗪噻肟;(6R,7R)-7-[[(2E)-2-(2-氨基-1,3-噻唑-4-基)-2-甲氧基亚氨乙酰]氨基]-3-[(2-甲基-5,6-二氧代-1H-1,2,4-三嗪-3-基)硫甲基]-8-氧代-5-硫-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸;氨噻三嗪头孢菌素; 头孢氨噻三嗪;头孢曲松粗品;头孢曲松钠; 头孢三嗪
目录号: V29480 纯度: ≥98%
头孢曲松 (Ro-139904;Biotrakson;Ro139904) 是一种头孢菌素类抗生素,具有广谱抗生素活性,用于治疗各种细菌感染。
Ceftriaxone CAS号: 73384-59-5
产品类别: New1
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
1mg
5mg
10mg
50mg
100mg
Other Sizes

Other Forms of Ceftriaxone:

  • 头孢曲松钠
  • 头孢曲松钠
  • Ceftriaxone-d3 disodium
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
头孢曲松(Ro-139904;Biotrakson;Ro139904)是一种头孢菌素类抗生素,具有广谱抗生素活性,用于治疗各种细菌感染。
生物活性&实验参考方法
药代性质 (ADME/PK)
吸收、分布和排泄
头孢曲松仅以注射方式给药,可肌注或静脉注射。口服头孢曲松的生物利用度低于1%。
头孢曲松主要经尿液排泄(33-67%)。其余部分经胆汁分泌,最终通过粪便排出体外。
健康患者静脉或肌注头孢曲松的表观分布容积为5.78至13.5升。脓毒症患者静脉或肌注头孢曲松的表观分布容积为6.48至35.2升。头孢曲松具有良好的脑脊液穿透性,可有效治疗细菌性脑膜炎。
健康成人接受0.15-3克头孢曲松后,血浆清除率为0.58至1.45升/小时。
头孢曲松的肾清除率为 0.32 至 0.73 升/小时。在重症监护病房患者中,头孢曲松的总药物清除率为 0.96 L/h(0.55-1.28 L/h),游离药物清除率为 1.91 L/h(1.46-6.20 L/h)。
代谢/代谢物
头孢曲松的代谢可忽略不计。
头孢曲松主要以原形经肾小球滤过(60%)和胆汁(40%)从尿液中排出(A633)。
排泄途径:33% 至 67% 的头孢曲松剂量以原形药物的形式经尿液排出,其余部分经胆汁分泌,最终以微生物学上无活性的化合物形式从粪便中排出。
半衰期:5.8-8.7 小时
生物半衰期
头孢曲松的半衰期为5.8-8.7小时。据估计,头孢曲松在中耳积液中的半衰期为25小时。
毒性/毒理 (Toxicokinetics/TK)
毒性概述
头孢曲松通过抑制细菌细胞壁中的粘肽合成发挥作用。头孢曲松的β-内酰胺部分与细菌细胞质膜上的羧肽酶、内肽酶和转肽酶结合。这些酶参与细胞壁合成和细胞分裂。头孢曲松通过与这些酶结合,导致缺陷细胞壁的形成和细胞死亡。
肝毒性
肠外给药头孢曲松与3%至46%的患者出现胆泥相关。儿童的发生率可能高于成人,并且与较高剂量、较长疗程以及可能存在的禁食或脱水有关。这种综合征被称为“假性胆结石症”,因为胆泥和结石主要成分是头孢曲松,停药后可自行消退,这意味着可以避免手术。大多数病例症状轻微或无症状。据报道,高达 5% 的假性胆结石症患者会出现明显的胆囊炎症状。通常情况下,即使出现胆绞痛,血清酶和胆红素水平也保持正常,但少数情况下会出现胆汁淤积性黄疸或胆石性胰腺炎,病情可能很严重,需要手术干预。胆泥和胆囊疾病症状可能在开始治疗后几天内出现,但通常在停用头孢曲松后迅速消退,尽管胆泥和胆结石可能在数月内仍可通过超声检查检测到。
头孢曲松还可能导致免疫过敏性胆汁淤积性肝炎,类似于其他头孢菌素类药物引起的肝炎。这种反应是特异性的,非常罕见。开始治疗后 1 至 4 周内会出现腹痛、恶心、瘙痒和黄疸等症状,停用抗生素后 1 至 2 周内症状可能会加重。血清酶升高呈胆汁淤积模式,并伴有发热、皮疹和嗜酸性粒细胞增多等免疫过敏反应。肝损伤通常较轻且具有自限性。
可能性评分:B(头孢曲松极有可能导致临床上明显的肝损伤,并可能导致胆泥和“假性结石”,这是由于头孢曲松在胆囊或胆道系统中的胆汁中结晶所致)。
妊娠和哺乳期用药
◉ 哺乳期用药概述
有限的信息表明,头孢曲松在乳汁中的浓度较低,预计不会对母乳喂养的婴儿造成不良影响。有报道称,头孢菌素类药物偶尔会扰乱婴儿的胃肠道菌群,导致腹泻或鹅口疮,但这些影响尚未得到充分评估。头孢曲松可用于哺乳期妇女。
◉ 对母乳喂养婴儿的影响
一位纯母乳喂养52天大婴儿的母亲出现了软组织感染。她接受了以下治疗:静脉注射替考拉宁400毫克,每12小时一次,共3次;然后每日400毫克,共5天;静脉注射头孢曲松1克,每日一次;外用莫匹罗星乳膏,每日两次。仔细的后续随访表明,她的婴儿没有出现不良反应。
◉ 对哺乳和母乳的影响
截至修订日期,未找到相关的已发表信息。
蛋白结合
头孢曲松的蛋白结合率为 95%。
毒性数据
LD50:>10000 mg/kg(口服,大鼠)
参考文献
:J Biol Chem, 2008. 283(19): p. 13116-23.
其他信息
药效学
头孢曲松是一种头孢菌素/头霉素类β-内酰胺类抗生素,用于治疗由敏感菌(通常为革兰氏阳性菌)引起的细菌感染。头孢曲松对革兰氏阳性需氧菌、革兰氏阴性需氧菌和厌氧菌均具有体外活性。头孢曲松的杀菌活性源于其抑制细胞壁合成,并通过与青霉素结合蛋白(PBPs)结合而发挥作用。头孢曲松对多种β-内酰胺酶(包括青霉素酶、头孢菌素酶和超广谱β-内酰胺酶)的水解作用稳定。然而,细菌对头孢曲松的耐药性通常是由于β-内酰胺酶水解、PBPs改变或细菌细胞通透性降低所致。头孢曲松不应与含钙的稀释剂/产品混合或通过同一静脉输液管输注,因为它们可能导致头孢曲松沉淀。使用头孢曲松还可能导致胆泥或胆囊假性结石。
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C18H18N8O7S3
分子量
554.579918384552
精确质量
554.046
CAS号
73384-59-5
相关CAS号
Ceftriaxone sodium hydrate;104376-79-6;Ceftriaxone sodium salt;74578-69-1;Ceftriaxone-d3 disodium;1132650-38-4
PubChem CID
5479530
外观&性状
Off-white to yellow solid powder
密度
2.0±0.1 g/cm3
熔点
155 °C
折射率
1.889
LogP
-0.77
tPSA
293.8
氢键供体(HBD)数目
4
氢键受体(HBA)数目
13
可旋转键数目(RBC)
8
重原子数目
36
分子复杂度/Complexity
1110
定义原子立体中心数目
2
SMILES
CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O
InChi Key
VAAUVRVFOQPIGI-SPQHTLEESA-N
InChi Code
InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
化学名
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMSO : ~31.25 mg/mL (~56.35 mM)
溶解度 (体内实验)
配方 1 中的溶解度: ≥ 2.5 mg/mL (4.51 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

配方 2 中的溶解度: ≥ 2.5 mg/mL (4.51 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。
*20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (4.51 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。


请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.8032 mL 9.0158 mL 18.0317 mL
5 mM 0.3606 mL 1.8032 mL 3.6063 mL
10 mM 0.1803 mL 0.9016 mL 1.8032 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
CTID: NCT06494072
Phase: Phase 4    Status: Recruiting
Date: 2024-11-20
Antibiotic Instillation in Appendicitis
CTID: NCT05470517
Phase: Phase 2    Status: Completed
Date: 2024-11-06
Early Antibiotics After Aspiration in ICU Patients
CTID: NCT05079620
Phase: Phase 4    Status: Terminated
Date: 2024-11-01
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
CTID: NCT06611111
PhaseEarly Phase 1    Status: Not yet recruiting
Date: 2024-10-22
Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline
CTID: NCT05980871
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-09-23
View More

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
CTID: NCT05294588
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19


Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
CTID: NCT05027516
Phase: Phase 4    Status: Completed
Date: 2024-08-02
Prophylactic Antibiotic in Subtalar Fusion Surgery
CTID: NCT06527989
Phase: Phase 2/Phase 3    Status: Not yet recruiting
Date: 2024-07-30
Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)
CTID: NCT06396078
Phase: Phase 4    Status: Recruiting
Date: 2024-07-29
Zoliflodacin in Uncomplicated Gonorrhoea
CTID: NCT03959527
Phase: Phase 3    Status: Completed
Date: 2024-07-26
Tebipenem Trial in Children With Shigellosis
CTID: NCT05121974
Phase: Phase 2    Status: Recruiting
Date: 2024-07-15
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
CTID: NCT02735707
Phase: Phase 3    Status: Recruiting
Date: 2024-07-12
A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia
CTID: NCT04041791
Phase: Phase 3    Status: Completed
Date: 2024-07-08
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea
CTID: NCT04010539
Phase: Phase 3    Status: Completed
Date: 2024-05-30
Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection
CTID: NCT02424461
Phase: Phase 3    Status: Completed
Date: 2024-05-01
Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth
CTID: NCT06349122
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-04-05
Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis
CTID: NCT05761405
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-02-08
Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury
CTID: NCT06220929
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-01-24
Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis
CTID: NCT03179384
Phase: Phase 4    Status: Completed
Date: 2023-11-18
Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea
CTID: NCT06090565
Phase: Phase 4    Status: Completed
Date: 2023-10-23
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
CTID: NCT03413384
Phase: Phase 2    Status: Recruiting
Date: 2023-10-16
PROPER Trial of Pain and Inflammation After Knee Arthroscopy
CTID: NCT05149287
Phase: Phase 2    Status: Terminated
Date: 2023-09-05
Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study
CTID: NCT05971550
Phase: Phase 3    Status: Not yet recruiting
Date: 2023-08-02
Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)
CTID: NCT05943223
Phase: Phase 2    Status: Not yet recruiting
Date: 2023-07-13
Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery
CTID: NCT05398081
Phase: Phase 2    Status: Completed
Date: 2023-05-26
Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery
CTID: NCT02996656
Phase: N/A    Status: Recruiting
Date: 2023-05-10
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
CTID: NCT00138801
Phase: Phase 3    Status: Completed
Date: 2023-05-06
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
CTID: NCT02473263
Phase: Phase 3    Status: Completed
Date: 2023-03-07
Antibiotics to Decrease Post ERCP Cholangitis
CTID: NCT03087656
Phase: Phase 4    Status: Recruiting
Date: 2023-03-06
Prophylactic Antibiotics in Admitted Cirrhotics
CTID: NCT04218695
Phase: Phase 4    Status: Completed
Date: 2023-03-03
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
CTID: NCT05654896
Phase: Phase 3    Status: Unknown status
Date: 2022-12-16
A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
CTID: NCT00591318
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2022-12-02
Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital
CTID: NCT02334124
Phase: N/A    Status: Completed
Date: 2022-11-08
Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis
CTID: NCT03012360
Phase: Phase 4    Status: Unknown status
Date: 2022-08-17
Propranolol on Post Stroke Immune Status and Infection
CTID: NCT05375240
Phase: Phase 2    Status: Unknown status
Date: 2022-05-16
Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection
CTID: NCT05216744
Phase: Phase 2    Status: Completed
Date: 2022-03-17
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
CTID: NCT04870138
Phase: Phase 1    Status: Completed
Date: 2021-12-02
A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals
CTID: NCT00000648
Phase: N/A    Status: Completed
Date: 2021-10-27
Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition
CTID: NCT05051163
Phase: Phase 2/Phase 3    Status: Unknown status
Date: 2021-09-30
New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea
CTID: NCT03294395
Phase: Phase 3    Status: Completed
Date: 2021-08-06
Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI
CTID: NCT04975945
Phase: Phase 4    Status: Unknown status
Date: 2021-07-26
Ceftriaxone and Jaundice in Neonates
CTID: NCT03133637
Phase:    Status: Completed
Date: 2021-04-06
Experimental Human Infection With Neisseria Gonorrhoeae
CTID: NCT03840811
Phase: Phase 1    Status: Completed
Date: 2021-03-23
Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis
CTID: NCT03794765
Phase: Phase 2    Status: Completed
Date: 2020-12-11
Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
CTID: NCT03560232
Phase: Phase 4    Status: Terminated
Date: 2020-09-11
First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition
CTID: NCT03174236
Phase: Phase 3    Status: Unknown status
Date: 2020-05-19
Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC
CTID: NCT01265173
Phase: Phase 4    Status: Completed
Date: 2020-04-06
Ceftriaxone in the Management of Bipolar Depression
CTID: NCT00566111
Phase: N/A    Status: Terminated
Date: 2020-03-31
Ceftriaxone as Home IV for Staph Infections
CTID: NCT04141787
Phase: Phase 4    Status: Unknown status
Date: 2019-10-28
A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
CTID: NCT02384200
Phase: Phase 4    Status: Completed
Date: 2019-08-22
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
CTID: NCT01659866
Phase: Phase 4    Status: Completed
Date: 2019-06-25
Study of Lyme Neuroborreliosis
CTID: NCT01635530
Phase: Phase 4    Status: Completed
Date: 2019-05-13
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
CTID: NCT02473640
Phase: Phase 1/Phase 2    Status: Completed
Date: 2018-11-27
Study on Early Lyme Neuroborreliosis
CTID: NCT00910533
Phase: N/A    Status: Unknown status
Date: 2018-10-16
Antibiotics for Klebsiella Liver Abscess Study
CTID: NCT01723150
Phase: Phase 4    Status: Completed
Date: 2018-08-27
The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
CTID: NCT01160640
Phase: Phase 2    Status: Completed
Date: 2018-07-10
Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
CTID: NCT02015637
Phase: Phase 3    Status: Terminated
Date: 2018-06-20
Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.
CTID: NCT02659033
Phase: Phase 3    Status: Completed
Date: 2018-05-21
Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair
CTID: NCT03449940
Phase: N/A    Status: Completed
Date: 2018-03-01
RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding
CTID: NCT03061604
Phase: N/A    Status: Completed
Date: 2017-11-14
Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
CTID: NCT02210325
Phase: Phase 3    Status: Completed
Date: 2017-09-11
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
CTID: NCT01371838
Phase: Phase 3    Status: Completed
Date: 2017-09-06
Optimising Antibiotic Treatment for Sick Malnourished Children
CTID: NCT02746276
Phase: Phase 2    Status: Unknown status
Date: 2017-07-02
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder
CTID: NCT00512616
Phase: Phase 2    Status: Withdrawn
Date: 2017-07-02
Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?
CTID: NCT02443285
Phase: Phase 3    Status: Unknown status
Date: 2017-06-20
Prehospital Antibiotics Against Sepsis Trial
CTID: NCT01988428
Phase: N/A    Status: Completed
Date: 2017-06-15
Antibiotic Treatment of Multiple Erythema Migrans
CTID: NCT01163994
Phase: N/A    Status: Unknown status
Date: 2017-05-05
Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration
CTID: NCT02561442
Phase: Phase 2/Phase 3    Status: Completed
Date: 2017-04-25
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
CTID: NCT02257918
Phase: Phase 2    Status: Completed
Date: 2017-03-22
Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)
CTID: NCT01254344
Phase: Phase 3    Status: Completed
Date: 2017-03-22
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
CTID: NCT00509106
Phase: Phase 3    Status: Completed
Date: 2017-03-14
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
CTID: NCT00035347
Phase: Phase 4    Status: Completed
Date: 2017-03-10
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
CTID: NCT00111644
Phase: Phase 2    Status: Completed
Date: 2016-11-02
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
CTID: NCT01421693
Phase: Phase 4    Status: Completed
Date: 2016-10-04
The Op
PNEUMONIA DOSING IN CRITICALLY ILL PATIENTS
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2021-11-25
An open label randomized controlled trial comparing the effect of ceftriaxone plus azithromycin versus ceftriaxone for the treatment of Neisseria gonorrhoeae on the resistome
CTID: null
Phase: Phase 4    Status: Completed
Date: 2021-11-04
Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2021-07-28
Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2020-02-11
Short-course antibiotic regimen compared to conventional antibiotic treatment for gram-positive cocci infective endocarditis: randomized clinical trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-12-10
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA, Completed
Date: 2019-12-04
Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL)
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2019-10-02
A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection
CTID: null
Phase: Phase 2, Phase 3    Status: Restarted, Completed
Date: 2019-06-26
Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-04-29
Pharmacokinetics of different antibiotics in cerebrospinal fluid in children with malignant brain tumors – a pilot study
CTID: null
Phase: Phase 1    Status: Ongoing
Date: 2018-09-27
The value of post-operative antibiotic therapy after laparoscopic appendectomy for complicated acute appendicitis (other than for generalized peritonitis): a prospective, randomized, placebo-controlled Phase III study.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2018-06-05
Shorter treatment of catheter related urinary tract infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2018-03-07
Phase II clinical trial to evaluate an antibiotic regimen pharmacokinetic applicable to outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2018-02-26
Right Dose, Right Now: Randomized Clinical Trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-01-11
Investigation of Pharmacokinetic of Antiinfective Therapy in Healthy Subjects and Severely Burned Patients Admitted to the ICU
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2017-07-26
Non-inferiority multicentre randomized controlled trial comparing short versus standard course postoperative antibiotic treatment for complex acute appendicitis
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-03-14
A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephalosporin treatment with or without vancomycin in paediatric patients aged from 3 months to less than 18 years with hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-12-02
Antimicrobial treatment in patients with ventilator-associated tracheobronchitis: a prospective randomized placebo-controlled double-blind multicenter trial
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2016-09-06
PREvention of Complications to Improve Outcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment.
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2016-02-03
Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (COVID-19)
CTID: null
Phase: Phase 4    Status: Trial now transitioned, Temporarily Halted, GB - no longer in EU/EEA, Ongoing
Date: 2015-09-16
A Phase 2/3, Randomized, Open-Label, Multi-center
CTID: null
Phase: Phase 2    Status: Temporarily Halted, Completed
Date: 2014-10-10
A randomised controlled trial to compare the clinical effectiveness and safety of gentamicin and ceftriaxone in the treatment of gonorrhoea.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-08-05
Essai randomisé contre placebo, multicentrique, de non-infériorité comparant l’efficacité d’un traitement antibiotique court de 14 jours versus 21 jours dans les prostatites aiguës non nosocomiales, à germes sensibles aux fluoroquinolones - PROSTASHORT
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-03-12
A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-01-02
A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects with Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus aureus
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2012-10-22
Prospective, Randomized, open label, European, multicenter study of the efficacy of the linezolid-rifampin combination versus standard of care in the treatment of Gram-positive prosthetic hip joint infection
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-10-08
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-07-18
Neuroborrelioosin epidemiologia, taudinkuva, diagnostiikka ja hoito
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-06-07
Individualizing duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: a non-inferiority, randomized, controlled trial.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-12-20
Estudio de la eficacia de la administración prolongada de antibióticos betalactámicos frente a la administración intermitente en el tratamiento de la infección causada por microorganismo sensibles pero con concentraciones mínimas inhibitorias altas
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2011-10-27
Etude multicentrique, de non infériorité, randomisée, ouverte, évaluant l’efficacité de deux Durées d’Antibiothérapie (6 semaines versus 12 semaines) dans le Traitement des Infections sur Prothèses Ostéo-articulaires, avec changement prothétique (en 1 temps ou 2 temps long) ou non (lavage articulaire)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-07-26
A prospective single blind randomised controlled study to compare the outcomes of patients with diabetes and clinically non-infected ischaemic and neuropathic foot ulcers treated with and without oral antibiotics
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2011-07-13
Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2011-06-22
Evaluation de l'efficacité et de la tolérance d'un traitement court de 7 jours par ceftriaxone intraveineux le 1er jour puis par cefixime per os du 2éme au 7éme jours dans la prise en charge aux urgences de la pyélonéphrite aigue simple chez la femme de 18 à 65 ans.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2011-04-18
Preventive Antibiotics in Stroke Study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-05-05
PLEASE Persistent Lyme Empiric Antibiotic Study Europe. A prospective, randomised study comparing two prolonged oral antibiotic strategies after initial intravenous ceftriaxone therapy for patients with symptoms of proven or possible persistent Lyme disease
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-04-29
Intraveneous induction theraphy followed by oral theraphy against exclusive oral theraphy: randomized trial for the treatment of Whipple's disease
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-01-05
A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-acquired Pneumonia in Pediatric Subjects Ages 8 to 17 Years Old
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-09-15
treatment of healthcare-associated pneumonia: a prospective, multicenter study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2009-03-23
Estudio piloto, en fase IV para evaluar la influencia de la asociación de descontaminación intestinal selectiva (DIS) con norfloxacino a antibioterapia estándar sobre la traslocación bacteriana y la actividad inflamatoria en pacientes con peritonitis bacteriana espontánea (PBE)
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-07-31
A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone in the Treatment of Adult Subjects with Community-Acquired Pneumonia
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-03-25
A national, prospective, randomized, open label study to asses the efficacy and safety of IV/PO moxifloxacin vs IV ceftriaxone + IV azithromicin followed by PO amoxicilline/clavulanate and PO claritromycin in subjects with community-acquired pneumonia
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2007-12-10
'A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone, with Adjunctive Clarithromycin, in the Treatment of Adult Subjects with Community-Acquired Pneumonia '
CTID: null
Phase: Phase 3    Status: Completed
Date: 2007-11-22
Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-09-25
Pharmacokinetics of Cetriaxon in bone
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2007-05-22
Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Ceftriaxone with/without Linezolid in Treatment of Subjects Hospitalized With Community-Acquired Pneumonia
CTID: null
Phase: Phase 3    Status: Completed
Date: 2006-10-10
A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-12-12
A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalization without evidence of Legionella
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-02-18
CEFTRIAXONE NEONATAL THERAPY: A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFECT OF CEFTRIAXONE ON HYPERBILIRUBINEMIA
CTID: null
Phase: Phase 4    Status: Ongoing
Date:
A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, NON INFERIORITY TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE, ORAL DOSE OF ZOLIFLODACIN COMPARED TO A COMBINATION OF A SINGLE INTRAMUSCULAR DOSE OF CEFTRIAXONE AND A SINGLE ORAL DOSE OF AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH UNCOMPLICATED GONORRHOEA
CTID: null
Phase: Phase 3    Status: Ongoing
Date:

相关产品
联系我们